Trimerin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trimerin

Quick Facts

Property Description
Active Ingredients Sulfamethoxazole, Trimethoprim
Form Tablet, Oral suspension, Solution for injection
Pharmacological Class Antibiotic (Antimicrobial)
Common Use Treating bacterial infections
Origin Synthetic (Fixed-dose combination)

What Type of Medicine is Trimerin?

Trimerin is a trade name for the generic compound Co-trimoxazole, defined as a synthetic, fixed-dose combination antibiotic and antimicrobial agent. This medicinal entity is a chemotherapeutic agent because its action involves targeted chemical inhibition of bacterial growth processes. Co-trimoxazole is widely recognized as an essential medicine with a clinically established efficacy and safety profile. Other popular brand names utilizing this precise formulation include Bactrim and Septra.


Composition and Available Forms of Trimerin

The medicine's identity is based on the precise, fixed combination of two active substances: Sulfamethoxazole, which belongs to the sulfonamide class, and Trimethoprim, which is a diaminopyrimidine. These components are chemically synthesized, confirming the drug’s synthetic origin. Trimerin is supplied in several standard pharmaceutical preparations, primarily including a tablet for oral intake, an oral suspension (liquid), and a sterile solution for injection administered intravenously. The availability of the oral suspension allows for flexible administration, often targeting pediatric or certain adult patient groups who may have difficulty swallowing tablets.


Why is Trimerin a Combination Antibiotic?

Trimerin is formulated as a combination to achieve a stronger, synergistic effect against susceptible bacteria than its individual components could manage alone. Its primary purpose is to leverage this unique dual-action strategy to deliver decisive bactericidal action, quickly and effectively stopping the proliferation of bacteria. This combination is recognized for its efficacy against a broad range of bacterial strains. The combined drug serves as a robust and powerful means to resolve bacterial infections, commonly used as an initial therapy against a wide spectrum of susceptible microorganisms.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Trimerin?

Possible Side Effects and Safety Information

The safety profile for Trimerin (Co-trimoxazole) is defined by categorized adverse reactions and specific constraints documented in official government regulatory labeling. Adverse effects are organized by frequency and the physiological system affected.

Classification of Common and Severe Adverse Reactions

Adverse effects listed as Very Common (ge 1/10) include laboratory changes such as hyperkalemia (increased potassium levels) and general nausea. Common (ge 1/100 to < 1/10) reactions primarily involve the gastrointestinal system (e.g., diarrhea) and the skin (e.g., rash).

The regulatory safety documents emphasize Serious Adverse Reactions, which are rare but clinically significant. These include severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and severe hematologic disorders like agranulocytosis and aplastic anemia. Serious hepatotoxicity, including fulminant hepatic necrosis, is also documented.


Population-Specific Safety Notes

Safety constraints apply to specific patient groups. Older adults are generally more susceptible to severe adverse reactions, especially those with pre-existing renal or hepatic impairment. The medication is strictly contraindicated in patients with known severe hypersensitivity to its components, significant hepatic damage, severe renal insufficiency where plasma concentration cannot be monitored, and infants under two months of age. Furthermore, certain reactions, such as severe skin reactions, are noted as being most likely to occur early in the course of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents mandate that any suspected overdose of Trimerin (Co-trimoxazole) requires individuals to seek emergency medical attention immediately and contact a Poison Help line.

Documented Overdose Manifestations

Acute overexposure is officially documented to present with gastrointestinal symptoms like nausea, vomiting, anorexia, and colic, alongside neurological effects such as dizziness, headache, confusion, and potential loss of consciousness.

Later or severe manifestations listed in regulatory information include serious outcomes such as blood dyscrasias, jaundice, hematuria, and crystalluria. Acute overdosage of the trimethoprim component is specifically associated with the potential for bone marrow depression.

Official Management and Considerations

The management of Trimerin overdose is defined by symptomatic and supportive treatment. Procedures such as gastric lavage or the induction of vomiting may be employed to remove unabsorbed drug. Haemodialysis may be useful for clearance. For the resulting blood toxicity, Leucovorin (folinic acid) is the documented intervention to manage chronic trimethoprim overdosage effects.

Monitoring of laboratory parameters for electrolyte imbalances and blood dyscrasias is required. Patients with severely impaired renal function, particularly the elderly, are noted to be at an increased risk of severe adverse effects due to prolonged component half-lives.

Therapeutic Uses of Trimerin

Trimerin (Co-trimoxazole) is commonly used across several therapeutic domains to address symptoms associated with susceptible bacterial infections and alleviate related distressing manifestations. Its use may assist with easing the overall symptom burden and supports general well-being during symptomatic phases.

It is relevant for conditions characterized by periods of heightened symptoms, including uncomplicated urinary tract infections (UTIs), acute exacerbations of chronic bronchitis, specific gastrointestinal infections like Shigellosis and traveler's diarrhea, and certain localized infections such as acute otitis media in children. A relevant application is the treatment and prophylaxis of the severe lung disease, Pneumocystis jirovecii Pneumonia (PJP), particularly in immunosuppressed individuals.

“The application of this medication is associated with symptomatic relief across domains where additional management of discomfort is required.”

This medication helps address groups of symptoms that may become intense or disruptive, such as dysuria (painful urination), systemic fever, disruptive acute diarrhea, and respiratory symptoms like persistent cough and dyspnea (shortness of breath).

Quick Fact: Relief for Acute Infection Symptoms
Primary Symptom Axis Symptoms related to systemic imbalance and physical discomfort
Common Scenario Applied in clinical settings that involve acute or unstable symptom patterns
Core Benefit Provides support that helps ease the overall symptom burden

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Trimerin — Official Regulatory Information

Official regulatory documents define strict criteria for Trimerin (co-trimoxazole) use, primarily based on patient age, organ function, and known hypersensitivities.


Scope Eligibility Status (Official Basis)
Populations Contraindicated Patients with known hypersensitivity to trimethoprim or sulfonamides; those with megaloblastic anemia due to folate deficiency; individuals with marked hepatic damage or acute porphyria.
Age-Related Rules Prohibited for infants younger than 2 months of age due to the risk of kernicterus. Use in elderly patients requires caution and dose monitoring due to heightened risk of adverse effects.
Pregnancy & Lactation Contraindicated in late-term pregnancy and for nursing mothers (especially neonates, premature, or jaundiced infants). Use in the first trimester is generally not recommended.
Condition-Based Restrictions Contraindicated in severe renal insufficiency (CrCl less than 15 mL per minute) when repeated monitoring is not possible. Patients with moderate renal impairment (CrCl 15 to 30 mL per minute) require a mandated dose adjustment.

Connection to the overall eligibility profile: The regulatory labeling establishes absolute prohibitions against use in patients with severe organ impairment (hepatic/renal) and specific hematologic/immune conditions, or in neonates. Use is otherwise restricted for groups like the elderly or those with moderate renal impairment, requiring modifications or increased caution as formally documented.

What should I know about interactions with other medicines?

This section outlines drug and substance interactions for Trimerin (Co-trimoxazole) as documented in official government regulatory sources.

Formally Restricted and Contraindicated Combinations

The co-administration of Trimerin is formally contraindicated with Dofetilide, an antiarrhythmic agent. This prohibition is due to the documented risk of significantly increased Dofetilide plasma concentrations, which can lead to life-threatening heart arrhythmias. Similarly, co-administration with Clozapine is contraindicated due to the documented risk of neutropenia. Use with Methenamine is generally advised against due to the risk of crystalluria.

Clinically Significant Exposure Alterations

Trimerin interferes with the clearance of several medicines, leading to increased plasma levels or prolonged half-life by inhibiting their metabolism or transport. This applies to:

  • Warfarin: Increased anticoagulant effect, requiring close monitoring.
  • Phenytoin: Increased serum concentrations, raising the potential for excessive effect.
  • Methotrexate: Increased free plasma levels due to displacement from protein-binding sites.
  • Digoxin: Documented increase in plasma levels, particularly in elderly patients.

Pharmacodynamic and Additive Risks

Additive effects are documented with drugs that manage blood potassium levels. Co-administration with ACE Inhibitors, ARBs, or Potassium-Sparing Diuretics (e.g., Spironolactone) carries a documented risk of hyperkalaemia (elevated potassium). Combining Trimerin with Thiazide Diuretics is associated with an increased risk of thrombocytopenia, especially in elderly patients.

Interaction with Non-Medicinal Substances

Regulatory documents note that co-administration with Folinic Acid supplements may reduce the antimicrobial efficacy of Trimerin. For the intravenous formulation, administration is contraindicated with products containing Propylene Glycol.

Mechanism of Action

Dual, Sequential Blockade of Bacterial Metabolism

Trimerin (Co-trimoxazole) produces a bactericidal effect through a unique, dual-action mechanism that targets the bacterial cell's mandatory folate synthesis pathway. Sulfamethoxazole competitively inhibits the enzyme Dihydropteroate Synthase (DHPS), while Trimethoprim acts on the subsequent enzyme, Dihydrofolate Reductase (DHFR). This two-step molecular block substantially depletes the active tetrahydrofolic acid pool.


Inhibiting DNA and Protein Precursors

The profound deficiency of active folate directly halts the synthesis of essential nucleic acid precursors, including purines and thymidine. This mechanistic cascade immediately prevents the bacterial cell from manufacturing the DNA and RNA required for replication, resulting in bacterial cell death. The mechanism exhibits selective toxicity, targeting only the bacterial pathway, and produces a synergistic effect that is greater than the effect of either drug alone.

Dosage and Administration Information

How to Use Trimerin — Administration Guidelines

Trimerin is the proprietary name for a medicine containing the active substance trimethoprim. The following instructions outline the proper use of trimethoprim. This information is procedural and does not describe what the medicine treats.

Administration Scope

Instruction Category Statement
Route of Administration Oral (by mouth)
Dosing Frequency Typically one or two times daily
Preparation Requirements Swallow tablets whole with a drink of water; liquid forms must be shaken before measuring the dose
Timing in Relation to Meals May be taken with or without food
Special Administration For long-term prevention (prophylaxis), administration at night may be specified to maximize concentration in the urine

Standard Use Protocol

  • Completing the Course: The full course of medicine must be finished as prescribed by the healthcare provider, even if symptoms begin to improve. Stopping early can prevent the complete resolution of the condition.
  • Missed-Dose Rules: If a dose is forgotten, it should be taken as soon as remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped entirely; a double dose must never be taken to compensate.
  • Dose Adjustment: Dosage for adults, children, and the elderly is determined by body weight or renal (kidney) function. Children under six years of age require a suitable liquid dosage form rather than tablets.

This procedural structure defines the standardized approach to using the medicine and governs the duration of therapy, the correct timing of doses, and required actions for specific patient groups.


Note: The trade name 'Trimerin' is referenced here, but the procedural data is based on the labeling of its active component, trimethoprim.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trimerin (Co-trimoxazole)


Evidence for Use in Acute Bacterial Infections

This section will summarize the structure of research, primarily from randomized controlled trials and comparative studies, that has evaluated this medicine's use for treating acute conditions like uncomplicated Urinary Tract Infections (UTIs), Shigellosis, and Traveler's Diarrhea, describing the populations and outcomes measured in those short-term studies.

Research exploring how symptoms change over time for acute bacterial infections has primarily relied on short-term Randomized Controlled Trials (RCTs). For uncomplicated UTIs, studies monitored outcomes related to physical discomfort and also measured if the bacteria were cleared from the body. Findings described patterns observed in the measurements of microbiological outcomes and patient-reported outcomes related to physical discomfort during the observed time intervals. However, results apply only to the populations studied, and data are still emerging, particularly regarding how the rising rates of antimicrobial resistance across different regions may impact these findings.

Evidence for Use in Severe Pulmonary and Respiratory Infections

This area of the research overview will detail the high-level evidence base, including systematic reviews and historical controlled trials, related to the treatment and prevention of the severe lung disease, Pneumocystis jirovecii Pneumonia (PJP), particularly focusing on the study designs used for immunocompromised patients.

The medicinal combination was studied for Pneumocystis jirovecii Pneumonia (PJP), with evidence primarily derived from historical RCTs and subsequent cohort studies. These studies were applied in research contexts involving fluctuating or unstable symptoms and monitored outcomes such as patient survival and measurements related to breathing status (e.g., oxygen levels). The research examined different treatment regimens in immunosuppressed individuals, most notably those with HIV/AIDS, but also in non-HIV immunocompromised groups like transplant recipients.

Research for PJP Treatment and Prevention (Prophylaxis)

Research related to PJP prevention (prophylaxis) utilized long-term cohort studies and double-blind RCTs. These trials explored outcomes capturing phases of heightened symptom activity, such as the rate at which PJP occurred in the observed populations over many months. However, long-term effects are not fully established, and evidence is limited for certain non-HIV patient groups who may be evaluated for this prophylactic regimen.

‍‍ Studies in Specific Patient Populations

Studies for this medicine have been evaluated in various populations based on age and underlying health conditions. Research was evaluated in pediatric patients for certain bacterial infections. Older adults was studied for the treatment of UTIs and other systemic infections, with observational settings evaluating potential changes in functional health. Immunosuppressed individuals were central to the PJP research, where findings describe group patterns related to prevention and treatment success. However, data for certain groups, particularly non-HIV patients requiring prophylaxis or those with complex comorbidities, remain insufficient, and follow-up durations were limited in some of the older trials. Research provides context but not individual predictions.

Key Studies & References

  1. WHO Model List of Essential Medicines (Co-trimoxazole listing)
  2. Burden of Shigella Among Children with Diarrhea in the Americas: A Systematic Review and Meta-Analysis
  3. Effectiveness and tolerability of short course co-trimoxazole, norfloxacin and levofloxacin in bacteriological cure of uncomplicated urinary tract infection in outpatient setting (RCT)

Frequently Asked Questions (FAQ)

Common questions about Trimerin (FAQ)

Q: What happens if a dose of Trimerin is missed?

Official documentation describes that if a dose is forgotten, the medicine is typically taken as soon as the oversight is noted. However, if it is almost time for the next scheduled dose, the missed dose is usually skipped entirely. Regulatory documents emphasize that taking a double dose to compensate for a forgotten dose is not advised.

Q: How quickly can someone generally expect to feel the effects of Trimerin?

Studies on the drug’s processing in the body show that the active components typically reach their highest concentration in the bloodstream approximately 1 to 4 hours after being taken orally. Patient-specific expectations regarding symptom improvement are typically reviewed with the prescribing healthcare provider.

Q: How long does the effect of one dose of Trimerin typically last?

The duration of the medicine's effect relates to the half-lives of the active components, which is documented to range from approximately 8 to 13 hours. This pharmacological data is consistent with the general administration frequency described in official product information.

Q: Is Trimerin safe to use during pregnancy, according to official documents?

Regulatory documents state that use is contraindicated (prohibited) in late-term pregnancy and for nursing mothers of premature or jaundiced infants. Use in the first trimester is generally not recommended because the drug's mechanism of action is associated with a potential for adverse developmental outcomes related to folate deficiency.

Q: What are the storage guidelines for Trimerin tablets?

Official storage guidelines specify that the medicine should be maintained at Controlled Room Temperature (typically 20 C to 25 C). The tablets should be kept in their tightly closed, original container and protected from excess heat, moisture, and light.

Q: What does official guidance say about discontinuing Trimerin?

Official guidance indicates that the full prescribed course of medicine should be completed as determined by the doctor. This is necessary even if a patient’s symptoms begin to improve before the full course is finished.

Q: What kind of monitoring is recommended when taking Trimerin (like blood tests)?

Official warnings indicate that close monitoring is often recommended, especially for patients with pre-existing conditions. This monitoring commonly includes checking blood potassium levels (due to the risk of hyperkalemia). Additionally, complete blood counts are often obtained regularly during prolonged therapy to monitor for potential hematologic issues.

Q: Why do official sources state that sudden stopping of Trimerin should be avoided?

Official sources describe that the sudden cessation of the medicine is discouraged because it may prevent the complete resolution of the bacterial condition. Stopping prematurely may also contribute to the development of antimicrobial resistance.

Q: What are the most common side effects patients report feeling when first starting Trimerin?

Commonly documented adverse reactions include gastrointestinal issues, such as nausea, vomiting, and loss of appetite, and skin reactions like a rash. Regulatory documents note that serious, though rare, skin reactions are most likely to occur early in the course of treatment.

Q: Is it common to feel tired after taking Trimerin?

Fatigue and a general feeling of weakness are documented adverse reactions listed in the official product information. These general effects are sometimes noted alongside other, rarer reactions like blood disorders.

Q: Does Trimerin interact with alcohol?

Some drug information sources suggest that combining Trimerin with alcohol is not advised. This is due to the potential for unpleasant side effects such as fast heartbeats, flushing, nausea, and vomiting.

Q: Can Trimerin affect the way my birth control works?

Official sources note that one of the drug’s components, sulfamethoxazole, may reduce the effects of ethinyl estradiol (a common component in some oral contraceptives) in some women. Patients typically review their need for alternative or additional birth control methods with their healthcare provider during use.

Q: Are there any warnings about combining Trimerin with over-the-counter pain relievers?

No specific general over-the-counter pain reliever is listed as a formal contraindication in regulatory labeling. However, it is customary for patients to inform their doctor about all non-prescription drugs they use, as caution is recommended when combining medications.

Q: Can older people (seniors) use Trimerin safely?

Official labeling specifies that the geriatric population can be treated with this medicine. However, use requires caution and dose monitoring because seniors are more susceptible to severe adverse reactions, especially if they have existing kidney or liver impairment.

Q: What is the guidance for using Trimerin in children?

The medicine is contraindicated (prohibited) for use in infants younger than 2 months of age. For children 2 months and older, the dosage is determined based on the child’s body weight and is calculated by the prescribing doctor.

Q: Is it true that Trimerin can cause changes in mood?

Official regulatory documents list several central nervous system effects. Depression, apathy, and nervousness are documented in regulatory literature as rare adverse reactions. More severe reactions like psychosis and hallucinations have also been reported.

Q: Is there a generic version of Trimerin available?

Trimerin is a trade name for the generic combination drug Co-trimoxazole. It is also referred to generically as sulfamethoxazole and trimethoprim (TMP/SMX) and is available under its non-branded generic name.

Q: Is Trimerin a habit-forming medicine?

Official regulatory documents, which contain specific warnings for drugs with abuse potential, do not classify this antibiotic as a habit-forming medicine. The labeling contains no information regarding potential for abuse, misuse, or physical dependence.

Q: Can Trimerin impact my ability to drive or operate machinery?

Adverse reactions affecting the central nervous system, such as dizziness, confusion, and ataxia (lack of coordination), are documented. Patients who experience these effects are generally advised to use caution and avoid driving or operating complex machinery until the medicine's effects are understood.

Q: Does Trimerin have a 'Black Box Warning' listed by the FDA?

The FDA has not issued a Boxed Warning (Black Box Warning) for this specific medication. However, the label does include severe WARNINGS regarding the potential for serious or fatal adverse reactions, which must be carefully reviewed by the prescriber.

Q: How is Trimerin described in official literature regarding its potential for misuse?

Official regulatory documents do not classify this antibiotic as having a potential for abuse, misuse, or physical dependence. The literature is silent on this topic, as the focus is on its antimicrobial properties.

Q: Can Trimerin cause weight changes?

While not listed as a common effect, weight gain or loss have been reported as adverse reactions. Patients are advised to consult their doctor if they experience unexpected or significant changes in body weight while using the medicine.

Q: Is Trimerin known to interact with herbal supplements?

Official guidance recommends that patients notify their doctor and pharmacist of all herbal products they are taking. This is important because many herbal supplements can potentially interfere with how prescription drugs are processed or increase the risk of certain side effects.

Q: What are the official recommendations if I feel like Trimerin isn't working?

Official patient instructions indicate that patients typically contact the prescribing physician if symptoms worsen, if there is no improvement, or if signs of a new infection develop. The doctor can then determine the appropriate course of action.

Q: Can Trimerin affect sleep patterns?

The official adverse reactions list includes insomnia (difficulty falling or staying asleep) as a possible, though less frequent, side effect affecting the central nervous system.

Q: What is the typical time frame for the maximum benefit of Trimerin to be seen?

The maximum clinical benefit, which is the complete resolution of the susceptible bacterial infection, is typically achieved upon the completion of the full prescribed course of therapy, as stated in the drug’s labeling requirements.

Q: Do research papers mention the long-term safety of Trimerin?

The clinical studies section addresses long-term use in the context of prophylaxis (prevention) for specific infections like PJP. However, official reviews state that long-term effects are not fully established and evidence is limited for certain patient groups, particularly those requiring long-term treatment.

Q: Does my diet need to change while taking Trimerin?

The medicine may be taken with or without food, and patients are generally advised to maintain a normal diet and to drink plenty of fluids. Individuals with a risk for hyperkalemia (high potassium) may review their intake of high-potassium foods with their healthcare provider.

Q: Can Trimerin cause allergic reactions?

Trimerin is contraindicated in patients with a known severe hypersensitivity to its active components (sulfonamides or trimethoprim). Serious allergic reactions, including anaphylaxis and severe skin reactions, are listed as documented warnings.

Q: What are the signs of a serious, but rare, side effect of Trimerin?

Official warnings document serious, rare side effects. Key signs include fever, widespread blistering (SJS/TEN), severe or bloody diarrhea, unusual paleness, or yellowing of the skin (jaundice). These signs are noted to require immediate medical attention.

Q: Is there a link between Trimerin and certain laboratory test results?

The official adverse reactions and warnings sections confirm the drug is associated with several lab changes. These include hyperkalemia (increased potassium), hyponatremia (low sodium), and various hematologic toxicities (e.g., anemia, thrombocytopenia), which often require patient monitoring.

Q: Can Trimerin interact with vitamins or mineral supplements?

The drug’s mechanism of action involves interfering with the synthesis process that utilizes folic acid (a B vitamin). The co-administration of Folinic Acid supplements is specifically noted in regulatory documents to reduce the antimicrobial efficacy of the medicine.

How should Trimerin be stored and disposed of?

How to Store and Dispose of Trimerin (Co-trimoxazole)

Trimerin must be stored at Controlled Room Temperature (CRT), typically between 20 C to 25 C (68 F to 77 F), with excursions permitted to 30 C. The medication must be kept in its tightly closed, original container and be protected from excess heat, moisture, and light. Liquid formulations should also be kept from freezing.

Handling and Child Safety

All forms of Trimerin must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Trimerin should be disposed of via a drug take-back program. If a take-back program is unavailable, mix the medicine with an undesirable substance (e.g., dirt, coffee grounds) in a sealed bag before placing it in the household trash. Do not dispose of this medicine by flushing down a toilet or pouring into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trimerin found in:

A-Z Index: